Think beyond the skin: 2014 canadian expert opinion paper on treating to target in plaque psoriasis

Journal of Cutaneous Medicine and Surgery

Volumn 19, Issue 1, 2015, Pages 22-27

  Gulliver, Wayne ^a   Lynde, Charles ^c   Dutz, Jan P ^c   Vender, Ronald B ^c   Yeung, Jensen ^c   Bourcier, Marc ^c   Dion, Pierre Luc ^c   Hong, Chi Ho ^c   Searles, Gordon ^c   Poulin, Yves ^c  

^a

^b Canada

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE;

ARTICLE; COMORBIDITY; DERMATOLOGY LIFE QUALITY INDEX; DIABETES MELLITUS; DISEASE SEVERITY; FEAR; FEASIBILITY STUDY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSURANCE; LONG TERM CARE; PATIENT SATISFACTION; PHYSICIAN GLOBAL ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUVA; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SKIN DISEASE ASSESSMENT; SYSTEMIC THERAPY; TREATMENT OUTCOME; CANADA; DERMATOLOGY; EXPERT WITNESS; PROCEDURES; PSORIASIS; SEVERITY OF ILLNESS INDEX; STANDARDS;

CANADA; DERMATOLOGY; EXPERT TESTIMONY; HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84940970985     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2014.13151     Document Type: Article

References (37)

1. Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013;29:528-42, doi:10.1016/j.cjca.2013.01.005.
2. McPherson R, Frohlich J, Fodor G, et al. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27, doi:10.1016/S0828-282X (06)70310-5.
3. Cheng AYY; CDA 2013 Clinical Practice Guidelines Steering Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013;37:137-8, doi:10.1016/j.jcjd.2013.04.005.
4. Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39: 1559-82, doi:10.3899/jrheum.110207.
5. Atar D, Birkeland KI, Uhlig T. "Treat to target": moving targets from hypertension, hyperlipidemia and diabetes to rheumatoid arthritis. Ann Rheum Dis 2010;69:629-30, doi:10.1136/ard.2010.128462.
6. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7, doi:10.1136/ard.2009.123919.
7. Lewiecki EM, Cummings SR, Cosman FT. Treat-to-target for osteoporosis: is now the time? J Clin Endocrinol Metab 2013;98: 946-53, doi:10.1210/jc.2012-3680.
8. Riddle MC, Rosenstock J, Gerich J, et al. The Treat-to-Target Trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6, doi:10.2337/diacare.26.11.3080.
9. Sitbon O, Galie N. Treat-to-target strategies in pulmonary arterial hypertension; the importance of using multiple goals. Eur Respir Rev 2010;19:272-8, doi:10.1183/09059180.00008210.
10. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011;303:1-10, doi:10.1007/s00403-010-1080-1.
11. Guenther L, Gulliver W. Psoriasis comorbidities. J Cutan Med Surg 2009;13 Suppl 2:S77-87.
12. Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis, June 2009. Available at: http://www.dermatology.ca/wp-content/uploads/2012/01/cdnpsori asisguidelines.pdf.
13. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019, doi:10.1111/j.1365-2133.2009.09505.x.
14. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis, May 2008 - July 2011. Available at: http://www.aad.org/education/clinical-guidelines/currentand- upcoming-guidelines/current-guidelines-and-guidelines-indevelopment.
15. Pathirana D, Ormoerod AD, Saiag P, et al. European S3 - Guidelines on the systemic treatment of psoriasis vulgaris: supported by the EDF/ EADV/IPC. J Eur Acad Dermatol Venerol 2009;23 Suppl 2:1-70.
16. Fredriksson T, PetterssonU. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44, doi:10.1159/000250839.
17. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64:ii65-8, doi:10.1136/ard.2004.031237.
18. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6, doi:10.1111/j.1365-2230.1994.tb01167.x.
19. Augustin M, Kruger K, Radtke ME, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter crosssectional study in Germany Dermatology 2008;216:366-72, doi:10.1159/000119415.
20. Dubertret T, Mrowietz U, Ranki A, et al. EUROPSO patient survey 2006. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155: 729-36, doi:10.1111/j.1365-2133.2006.07405.x.
21. Nast A, Erdmann R, Hoeflich V, et al. Do guidelines change the way we treat? Studying private practitioners' prescription behavior before and after the publication of the German Psoriasis Guidelines. Arch Dermatol Res 2009;301:553-9, doi:10.1007/s00403-009-0978-y.
22. Poulin Y, Papp KA, Wasel NR, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010;49:1368-75, doi:10.1111/j.1365-4632.2010.04660.x.
23. Maza A, Richard MA, Aubin F, et al. Significant delay in systemic treatment introduction in moderate to severe psoriasis: a prospective multicenter observational study in outpatients from hospital dermatology department in France. Br J Dermatol 2012; 167:643-8, doi:10.1111/j.1365-2133.2012.10991.x.
24. Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol 2012;67:76-85, doi:10.1016/j.jaad.2011.06.035.
25. Kimball AB, Gieler U, Linder D, et al. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24:989-1004.
26. Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011;164 Suppl 1:1-14, doi:10.1111/j.1365-2133.2011.10280.x.
27. Abuabara K, Wan J, Troxel AB, et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013;68:262-9, doi:10.1016/j.jaad.2012.07.007.
28. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9, doi:10.1056/NEJMoa1109997.
29. Mrowietz U, de Jong EMGJ, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2013 Feb 26. [Epub ahead of print].
30. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124:775e1-6.
31. Mrowietz U, Guérin A, Gupta S, Mulani P. Comorbidity prevalence in psoriasis: a meta-analysis. Poster presentation at the 68th Annual Meeting of the American Academy of Dermatology; 2010March 5-9; Miami Beach, FL.
32. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 2010;163:586-92, doi:10.1111/j.1365-2133.2010.09941.x.
33. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol2008;159Suppl2:2-9, doi:10.1111/j.1365-2133.2008.08779.x.
34. Khalid U, Hansen PR, Gislalson GH, et al. Psoriasis and new-onset diabetes mellitus - a Danish nationwide cohort study. Diabetes Care 2013. [Epub ahead of print]
35. Ahelhoff O. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270:147-57, doi:10.1111/j.1365-2796.2010.02310.x.
36. Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012;148:1244-50, doi:10.1001/archdermatol.2012.2502.
37. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011;164:1091-6, doi:10.1111/j.1365-2133.2011.10213.x.